Zai Lab Limited ZLAB
Set alert
At close · Oct 30
After hours · Oct 30, 4:51 PM ET
- YTD
- +25.11%
- 1 year
- -13.52%
- Open
- 22.30
- Prev close
- 22.36
- Mkt cap
- 2.74B
- Vol
- 637.84K
- Avg vol
- 1.04M
- EPS
- -1.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.83
- High
- 22.43
- Forward P/E
- -10.46
- Beta
- 0.72
- Short ratio
- 10.97
- Inst. own
- 34.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 25.02
- 200-d avg
- 20.97
- 1y target
- 33.48
6M chart
Events in this range
- May 7, 2026Earnings: -0.46; estimate -0.52616; surprise 12.57%
- May 8, 2026Rating: Citigroup · Buy → Buy
- Aug 6, 2026Earnings: -0.46; estimate -0.67939; surprise 32.29%
- Aug 7, 2026Rating: Citigroup · Buy → Buy
Signals (27)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 27, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Overbought | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 24, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
Key statistics
- Market cap
- 2.74B
- Enterprise value
- 2.15B
- Trailing P/E
- 0.00
- Forward P/E
- -10.46
- PEG ratio
- 0.00
- Price / sales
- 6.09
- Price / book
- 4.08
- EPS (TTM)
- -1.70
- Beta
- 0.72
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -41.86%
- Revenue (TTM)
- 449.61M
- Revenue growth
- -3.30%
- Free cash flow
- -83.96M
- Total cash
- 617.52M
- Total debt
- 254.58M
- Return on equity
- -26.91%
- Shares outstanding
- 124.15M
- Short % of float
- 8.00%
- 50-day average
- 25.02
- 200-day average
- 20.97
Analyst view
Consensus: strong buy
- Target (low)
- 24.25
- Target (mean)
- 33.48
- Target (high)
- 50.00
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.56423.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.56423 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.67939 | -0.46 | +0.22 | +32.29% |
| May 7, 2026 | Mar 31, 2026 | -0.52616 | -0.46 | +0.07 | +12.57% |
| Feb 26, 2026 | Dec 31, 2025 | -0.44 | -0.46 | -0.02 | -4.55% |
| Nov 6, 2025 | Sep 30, 2025 | -0.28 | -0.33 | -0.05 | -17.86% |
| Aug 7, 2025 | Jun 30, 2025 | -0.37 | -0.37 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| May 8, 2026 | Citigroup | main | Buy | Buy |
| Mar 18, 2026 | JP Morgan | main | Overweight | Overweight |
| Feb 27, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Feb 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Jan 7, 2026 | UBS | init | — | Buy |
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- zailaboratory.com
News
- Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript
- Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
- Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3
- Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
- Zai Lab Announces $250 Million Private Placement
- Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
- Zai Lab Limited Unsponsored ADR (ZLAB) – What Are Brokerages Thinking About This Stock?
- Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
- Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey
- Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)
Your note
Sign in to keep a note on ZLAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMADO RAFAEL | President | Sale | Apr 5, 2026 | 57,022 |
| DIEKMAN JOHN DAVID | Director | Stock Award(Grant) | Jun 16, 2026 | 122,140 |
| DU YING SAMANTHA | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2026 | 1,221,400 |
| GAYNOR RICHARD BRIAN M.D. | Director | Purchase | Jun 30, 2026 | 80,737 |
| LEUNG NISA BERNICE WING-YU | Director | Stock Award(Grant) | Jun 16, 2026 | 96,297 |
| MOULDER LEON OLIVER JR. | Director | Stock Award(Grant) | Jun 16, 2026 | 94,973 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 5.78% | 6,574,032 | 145.09M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.39% | 6,137,627 | 135.46M | Jun 29, 2026 |
| RA Capital Management, L.P. | 5.05% | 5,743,533 | 126.76M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 2.96% | 3,369,034 | 74.35M | Jun 29, 2026 |
| FMR, LLC | 2.47% | 2,815,214 | 62.13M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 2.03% | 2,315,480 | 51.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BARON SELECT FUNDS-Baron Emerging Markets Fund | 1.20% | 1,370,904 | 30.26M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.65% | 740,494 | 16.34M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.29% | 331,780 | 7.32M | Aug 30, 2026 |
| abrdn World Healthcare Fund | 0.27% | 311,294 | 6.87M | Jun 29, 2026 |
| Tema ETF Trust-Tema Oncology ETF | 0.17% | 196,972 | 4.35M | May 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.12% | 132,344 | 2.92M | Aug 30, 2026 |